US Patent:
20120129837, May 24, 2012
Inventors:
Wieslaw M. Cholody - Frederick MD, US
Yi Zang - Princeton Junction NJ, US
Norman E. Ohler - Ijamsville MD, US
Sheela Chellappan - Germantown MD, US
Janak Padia - Germantown MD, US
Karina Zuck - Derwood MD, US
Jeffrey W.H. Watthey - Frederick MD, US
Zoe Ohler - Ijamsville MD, US
Jeffrey Strovel - Laurel MD, US
International Classification:
A61K 31/553
A61K 31/473
A61K 31/18
A61K 31/4545
A61K 31/5377
A61K 31/55
A61K 31/551
C07D 403/12
C07D 401/14
C07C 311/37
C07D 401/12
C07D 413/12
A61P 35/00
A61P 35/04
A61K 31/395
US Classification:
51421115, 514183, 514297, 514603, 514316, 5142318, 51421703, 514218, 540480, 546104, 552222, 552210, 546189, 546191, 544 79, 540596, 540575, 540544
Abstract:
Chemical agents, such as disulfonamide derivatives of fluorene, anthracene, xanthene, dibenzosuberone and acridine, and similar heterocyclic ring structures, including salts thereof, that act as anti-cancer and anti-tumor agents, especially where such agents modulate the activity of the Wnt/β-catenin signaling pathway, and serve to reduce β-catenin levels present in cells, such as cancer cells, or where the agents modulate levels of gene expression in cellular systems, including cancer cells, are disclosed, along with methods for preparing such agents, as well as pharmaceutical compositions containing such agents as active ingredients and methods of using these as therapeutic agents.